

Sengenics collaborates with GSK focusing on immunology

22 June 2020 | News

The collaboration will leverage Sengenics' proprietary KREX™ technology to validate novel autoantibody biomarkers in patients with autoimmune diseases.



Singapore based Sengenics, a functional proteomics company, has announced that it has entered into a research collaboration agreement with GlaxoSmithKline (GSK).

The collaboration will combine Sengenics' functional proteomics capabilities with GSK's scientific expertise in immunology, especially in drug discovery.

The collaboration will leverage Sengenics' proprietary KREX™ technology to validate novel autoantibody biomarkers in patients with autoimmune diseases.

These biomarkers were identified using the IMMUNOME™ protein array, a KREX™-based array with functionally validated, full-length, correctly folded proteins.